These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8796866)

  • 41. Clinical studies of antisense oligonucleotides for cancer therapy.
    Orr RM; Dorr FA
    Methods Mol Med; 2005; 106():85-111. PubMed ID: 15375314
    [No Abstract]   [Full Text] [Related]  

  • 42. Gene therapy for cancer.
    Kipps TJ
    J Hematother; 1993; 2(3):367-72. PubMed ID: 7921998
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biological response modifiers.
    Clark JW
    Cancer Chemother Biol Response Modif; 1996; 16():239-73. PubMed ID: 8639384
    [No Abstract]   [Full Text] [Related]  

  • 44. Role of biological therapies in the development of personalized medicine.
    Jain KK
    Expert Opin Biol Ther; 2012 Jan; 12(1):1-5. PubMed ID: 22107592
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy and monoclonal antibody therapies.
    Schuster JM; Bigner DD
    Curr Opin Oncol; 1992 Jun; 4(3):547-52. PubMed ID: 1498162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms.
    Zhang R; Wang H; Agrawal S
    Curr Cancer Drug Targets; 2005 Feb; 5(1):43-9. PubMed ID: 15720188
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biological therapy of ovarian cancer: current directions.
    Bookman MA
    Semin Oncol; 1998 Jun; 25(3):381-96. PubMed ID: 9633851
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biological response modifiers.
    Clark JW
    Cancer Chemother Biol Response Modif; 1988; 10():434-59. PubMed ID: 3079394
    [No Abstract]   [Full Text] [Related]  

  • 49. [Immunological tumor therapy].
    Dietrich K; Theobald M
    Internist (Berl); 2015 Aug; 56(8):907-16; quiz 917. PubMed ID: 26187335
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antisense oligonucleotides in cancer.
    Castanotto D; Stein CA
    Curr Opin Oncol; 2014 Nov; 26(6):584-9. PubMed ID: 25188471
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multi-specific antibodies for cancer immunotherapy.
    Jachimowicz RD; Borchmann S; Rothe A
    BioDrugs; 2014 Aug; 28(4):331-43. PubMed ID: 24638872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
    Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
    Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MicroRNAs as targets for antisense-based therapeutics.
    Stenvang J; Kauppinen S
    Expert Opin Biol Ther; 2008 Jan; 8(1):59-81. PubMed ID: 18081537
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antisense '97: a roundtable on the state of the industry.
    Nat Biotechnol; 1997 Jun; 15(6):519-24. PubMed ID: 9181572
    [No Abstract]   [Full Text] [Related]  

  • 55. Antisense gene therapy trials underway in patients with CML.
    Oncology (Williston Park); 1996 Sep; 10(9):1411. PubMed ID: 8882929
    [No Abstract]   [Full Text] [Related]  

  • 56. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
    Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monoclonal antibody to treat lymphoma.
    Marwick C
    JAMA; 1997 Aug; 278(8):616, 618. PubMed ID: 9272879
    [No Abstract]   [Full Text] [Related]  

  • 58. Molecular therapy in ocular wound healing.
    Cordeiro MF; Schultz GS; Ali RR; Bhattacharya SS; Khaw PT
    Br J Ophthalmol; 1999 Nov; 83(11):1219-24. PubMed ID: 10535844
    [No Abstract]   [Full Text] [Related]  

  • 59. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biological response modifier--immunotherapeutic approaches in pancreatic cancer.
    Schmiegel W
    Hepatogastroenterology; 1989 Dec; 36(6):456-8. PubMed ID: 2693301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.